Jagmeet Singh Sets March 1 Deadline For Pharmacare Bill, Warns Of ‘Repercussions’ If Trudeau’s Government Doesn’t Follow Through
NDP Leader Jagmeet Singh has sternly warned Prime Minister Justin Trudeau about the potential breakdown of their supply-and-confidence agreement should the government fail to introduce a satisfactory pharmacare bill by March 1.
“I put him on notice that we expect that by March 1, if not there will be repercussions … if the government doesn’t follow through,” Singh said.
This ultimatum comes after what Singh described as a “tough” meeting with Trudeau, emphasizing the NDP’s firm stance on the implementation of a national pharmacare plan, a key component of their partnership aimed at supporting the minority Liberal government in exchange for progress on shared progressive initiatives.
Singh’s declaration underscores the NDP’s unwillingness to tolerate further delays in establishing a framework for a nationwide drug program, a commitment that was integral to the two parties’ agreement, designed to ensure parliamentary stability until June 2025.
Related: NDP’s Jagmeet Singh Doesn’t Want To Work With Liberals Again
The NDP leader accused the Liberals of attempting to propose a “mixed system” pharmacare model, which he believes would cater to pharmaceutical and insurance industries, contrary to the NDP’s vision of a single-payer, universal system.
Despite the original agreement stipulating the enactment of a “Canada Pharmacare Act” by the end of 2023, the deadline was extended after the government failed to table a bill within the agreed timeframe. Singh has now signaled that the NDP expects additional steps to be taken, and said he’ll give more specifics in the coming days.
“We made our demands very clear and our expectations very clear. The prime minister and the Liberal government now know where we stand, and we’ll see what happens on March 1,” Singh said.
Information for this story was found via CTV News, and the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
